Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 2Ovarian Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 8Paclitaxel 7Taxes 6Lapatinib 6Docetaxel 5veliparib 3Tamoxifen 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3sargramostim 2liposomal doxorubicin 2ixabepilone 2cediranib 2Vorinostat 2Vinorelbine 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Mifepristone 2MK 2206 2Interleukin-12 Subunit p35 2Interleukin-12 2Granulocyte-Macrophage Colony-Stimulating Factor 2Goserelin 2Gemcitabine 2Filgrastim 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms, Male × Indomethacin × Clear all
NCT02950259 2025-12-03

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Providence Health & Services

Phase 1 Completed
16 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡